JBS · Jbs N.V.
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Earnings Per Share Attributable to JBS non-GAAP | $0.43 | Six Months Ended 2026 | — |
| Adjusted EBITDA USGAAP non-GAAP | $1.26B | 2Q26 | — |
GAAP → non-GAAP reconciliationGAAP Adjusted EBITDA (IFRS) 1.43B
-85.9M Leasing adjustments
-18.6M Inventory adjustments at market value
-68.6M Biological assets adjustments
+0.3M Other adjustments
= Adjusted EBITDA (USGAAP) 1.26B
|
|||
| Adjusted Net income Attributable to JBS non-GAAP | $459.6M | Six Months Ended 2026 | — |
| Adjusted Operating Income IFRS non-GAAP | $790.2M | 2Q26 | — |
GAAP → non-GAAP reconciliationGAAP Total Adjusted EBITDA 1.43B
-639.1M (-) Depreciation and amortization
= Adjusted Operating Income (IFRS) 790.2M
|
|||
| Adjusted Operating Income USGAAP non-GAAP | $865.9M | 2Q26 | — |
GAAP → non-GAAP reconciliationGAAP Adjusted Operating Income IFRS 790.2M
-16.5M Leasing adjustments
-18.6M Inventory adjustments at market value
+110.1M Biological assets adjustments
+0.6M Other adjustments
= Adjusted Operating Income (USGAAP) 865.9M
|
|||
| Free Cash Flow | $36.4M | Six Months Ended 2026 | — |
| Gross Debt/Adjusted EBITDA | 3.71 | 2Q26 | — |
| Interest Coverage | 5 | Last twelve months ended June 30, 2026 | — |
| ROE | 13.4% | Last twelve months ended June 30, 2026 | — |
| ROIC | 13.4% | Last twelve months ended June 30, 2026 | — |
| Total Adjusted EBITDA non-GAAP | $6.11B | Last twelve months ended June 30, 2026 | — |
| Total Gross Debt | $22.65B | 2Q26 | — |
| Total Net Debt | $18.96B | 2Q26 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Packaged Foods — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JBS
this stock
Jbs N.V.
|
$14.39B | -4.6% | — | — | 3.3% |
|
KHC
Kraft Heinz Co
|
$29.35B | +5.9% | -0.1% | — | 7.3% |
|
GIS
General Mills Inc
|
$21.34B | -14.0% | +4.1% | — | 9.2% |
|
MKC
Mccormick & Co Inc
|
$14.50B | -17.1% | +1.7% | 9.0 | 5.1% |
|
HRL
Hormel Foods Corp /De/
|
$13.39B | +3.0% | +1.6% | 28.6 | 3.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JBS | +4.8% | +12.2% | -17.3% | -1.9% | -4.7% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +5.2% | +9.3% | -28.9% | -4.9% | -17.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.